Zobrazeno 1 - 10 of 41 pro vyhledávání: '"Markus F Scheerer"'
1
Akademický článek
Bidirectional modulation of TCA cycle metabolites and anaplerosis by metformin and its combination with SGLT2i
Autor: Makoto Harada, Jonathan Adam, Marcela Covic, Jianhong Ge, Stefan Brandmaier, Caroline Muschet, Jialing Huang, Siyu Han, Martina Rommel, Markus Rotter, Margit Heier, Robert P. Mohney, Jan Krumsiek, Gabi Kastenmüller, Wolfgang Rathmann, Zhongmei Zou, Sven Zukunft, Markus F. Scheerer, Susanne Neschen, Jerzy Adamski, Christian Gieger, Annette Peters, Donna P. Ankerst, Thomas Meitinger, Tanya L. Alderete, Martin Hrabe de Angelis, Karsten Suhre, Rui Wang-Sattler
Publikováno v: Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-14 (2024)
Abstract Background Metformin and sodium-glucose-cotransporter-2 inhibitors (SGLT2i) are cornerstone therapies for managing hyperglycemia in diabetes. However, their detailed impacts on metabolic processes, particularly within the citric acid (TCA) c
Externí odkaz: https://doaj.org/article/5843fb532be04b438b4aad8078618b3c
Zobrazit plný text záznamu
2
Akademický článek
Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes
Autor: Jens Aberle, Markus Menzen, Sebastian M. Schmid, Christoph Terkamp, Elmar Jaeckel, Katja Rohwedder, Markus F. Scheerer, John Xu, Weifeng Tang, Andreas L. Birkenfeld
Publikováno v: Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Abstract Recent studies have shown that high-risk patients with type 2 diabetes mellitus (T2DM) treated with sodium glucose cotransporter 2 (SGLT2) inhibitors have improved cardiovascular (CV) outcomes. In an exploratory analysis of data from the EMP
Externí odkaz: https://doaj.org/article/4ef2b8e15fa34ef09f3620b326bc5c84
Zobrazit plný text záznamu
3
Akademický článek
Validation of Candidate Phospholipid Biomarkers of Chronic Kidney Disease in Hyperglycemic Individuals and Their Organ-Specific Exploration in Leptin Receptor-Deficient db/db Mouse
Autor: Jialing Huang, Marcela Covic, Cornelia Huth, Martina Rommel, Jonathan Adam, Sven Zukunft, Cornelia Prehn, Li Wang, Jana Nano, Markus F. Scheerer, Susanne Neschen, Gabi Kastenmüller, Christian Gieger, Michael Laxy, Freimut Schliess, Jerzy Adamski, Karsten Suhre, Martin Hrabe de Angelis, Annette Peters, Rui Wang-Sattler
Publikováno v: Metabolites, Vol 11, Iss 2, p 89 (2021)
Biological exploration of early biomarkers for chronic kidney disease (CKD) in (pre)diabetic individuals is crucial for personalized management of diabetes. Here, we evaluated two candidate biomarkers of incident CKD (sphingomyelin (SM) C18:1 and pho
Externí odkaz: https://doaj.org/article/661cd130a4334bf6a5cdd3686c6d091f
Zobrazit plný text záznamu
5
Add‐on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study
Autor: Ido Muller, Olga Kordonouri, Moshe Phillip, Revital Nimri, Natasa Bratina, Klemen Dovc, Eran Atlas, Thomas Danne, Markus F. Scheerer, Thekla von dem Berge, Torben Biester, Tadej Battelino
Publikováno v: Diabetes, Obesity and Metabolism. 23:599-608
AIM To investigate the effect of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on glucose levels overnight and during the following day after two unannounced meals under full closed loop (FCL) conditions. MATERIALS AND METHODS For this
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a09f45c63ca8f70df7d88643add0e5d0
https://doi.org/10.1111/dom.14258
Zobrazit plný text záznamu
6
Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT ‐1 and ‐2 studies
Autor: Paresh Dandona, Depict Investigators, Depict, Niki Arya, Simon Heller, Paolo Di Bartolo, Lars Hansen, Richard M. Bergenstal, Eiichi Araki, Moshe Phillip, John Xu, Markus F. Scheerer, Nayyar Iqbal, Chantal Mathieu, Marcus Lind, Fredrik Thoren
Publikováno v: Diabetes, Obesity & Metabolism
Aims This pooled analysis of the DEPICT-1 and -2 trials aimed to evaluate the efficacy and safety of adjunct dapagliflozin therapy in patients with type 1 diabetes (T1D). Materials and methods DEPICT-1 and -2 were randomized, double-blind, parallel-g
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eeabb346397e1e4e7778837ac220da0
https://doi.org/10.1111/dom.14248
Zobrazit plný text záznamu
7
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials
Autor: Johan Jendle, Paresh Dandona, John Xu, Nayyar Iqbal, Enrico Repetto, Markus F. Scheerer, Steven V. Edelman, Per-Henrik Groop, Fredrik Thoren, Moshe Phillip, Pieter Gillard, Chantal Mathieu
Publikováno v: The Lancet Diabetes & Endocrinology. 8:845-854
Summary Background The DEPICT-1 and DEPICT-2 studies showed that dapagliflozin as an adjunct to insulin in individuals with inadequately controlled type 1 diabetes improved glycaemic control and bodyweight, without increase in risk of hypoglycaemia.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00f7846f46b1b29ed6f481ec3393eac5
https://doi.org/10.1016/s2213-8587(20)30280-1
Zobrazit plný text záznamu
8
Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme
Autor: Jason Gordon, Amarjeet Tank, Hayley Bennet, Lee Beresford-Hulme, Phil McEwan, Markus F. Scheerer, Thomas Danne, Christopher Edmonds, Fredrik Thoren
Publikováno v: Diabetes Therapy
Introduction Dapagliflozin is an orally active inhibitor of sodium-glucose co-transporter 2 (SGLT2) that is indicated for use in adults with type 1 diabetes (T1DM) (with a body mass index (BMI) of at least 27 kg/m2 in Europe, no such BMI limit in Jap
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76c497fa6104ace37b10d6a8d383c672
http://europepmc.org/articles/PMC7192983
Zobrazit plný text záznamu
9
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
Autor: Peter, Rossing, Stefan D, Anker, Gerasimos, Filippatos, Bertram, Pitt, Luis M, Ruilope, Andreas L, Birkenfeld, Janet B, McGill, Sylvia E, Rosas, Amer, Joseph, Martin, Gebel, Luke, Roberts, Markus F, Scheerer, George L, Bakris, Rajiv, Agarwal
Publikováno v: Diabetes Care 45, 2991–2998 (2022)
Rossing, P, Anker, S D, Filippatos, G, Pitt, B, Ruilope, L M, Birkenfeld, A L, McGill, J B, Rosas, S E, Joseph, A, Gebel, M, Roberts, L, Scheerer, M F, Bakris, G L & Agarwal, R 2022, ' Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment : The FIDELITY Analysis ', Diabetes Care, vol. 45, no. 12, pp. 2991-2998 . https://doi.org/10.2337/dc22-0294
OBJECTIVE Finerenone reduced the risk of kidney and cardiovascular events in people with chronic kidney disease (CKD) and type 2 diabetes in the FIDELIO-DKD and FIGARO-DKD phase 3 studies. Effects of finerenone on outcomes in patients taking sodium
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4517d3c98de108bcc8e556fc93262d7
https://pubmed.ncbi.nlm.nih.gov/35972218
Zobrazit plný text záznamu
10
Kidney outcomes with finerenone: An analysis from the FIGARO-DKD study
Autor: Luis M Ruilope, Bertram Pitt, Stefan D Anker, Peter Rossing, Csaba P Kovesdy, Roberto Pecoits-Filho, Pablo Pergola, Amer Joseph, Andrea Lage, Nicole Mentenich, Markus F Scheerer, George L Bakris
Publikováno v: ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
Ruilope, L M, Pitt, B, Anker, S D, Rossing, P, Kovesdy, C P, Pecoits-Filho, R, Pergola, P, Joseph, A, Lage, A, Mentenich, N, Scheerer, M F & Bakris, G L 2023, ' Kidney outcomes with finerenone : an analysis from the FIGARO-DKD study ', Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association-European Renal Association, vol. 38, no. 2, pp. 372-383 . https://doi.org/10.1093/ndt/gfac157
Background In FIGARO-DKD, finerenone reduced the risk of cardiovascular events in patients with type 2 diabetes (T2D) and stage 1–4 chronic kidney disease (CKD). In FIDELIO-DKD, finerenone improved kidney and cardiovascular outcomes in patients wit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4230ea9305117ea4d08e6a423c7c685
http://hdl.handle.net/11268/11297
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje